Novo Nordisk A/S (NVO)
- Previous Close
67.02 - Open
69.44 - Bid 69.26 x 1000
- Ask 69.29 x 800
- Day's Range
68.70 - 70.00 - 52 Week Range
57.00 - 148.15 - Volume
4,658,794 - Avg. Volume
9,706,381 - Market Cap (intraday)
301.32B - Beta (5Y Monthly) 0.21
- PE Ratio (TTM)
19.58 - EPS (TTM)
3.53 - Earnings Date Aug 6, 2025
- Forward Dividend & Yield 1.62 (2.41%)
- Ex-Dividend Date Mar 31, 2025
- 1y Target Est
90.39
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
www.novonordisk.com77,406
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: NVO
View More
Related Videos: NVO
Performance Overview: NVO
Trailing total returns as of 5/20/2025, which may include dividends or other distributions. Benchmark is OMX Copenhagen 25 Index (^OMXC25) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NVO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NVO
View MoreValuation Measures
Market Cap
284.34B
Enterprise Value
295.92B
Trailing P/E
19.03
Forward P/E
16.37
PEG Ratio (5yr expected)
1.01
Price/Sales (ttm)
6.57
Price/Book (mrq)
14.33
Enterprise Value/Revenue
6.51
Enterprise Value/EBITDA
13.46
Financial Highlights
Profitability and Income Statement
Profit Margin
34.51%
Return on Assets (ttm)
23.29%
Return on Equity (ttm)
88.12%
Revenue (ttm)
303.14B
Net Income Avi to Common (ttm)
104.62B
Diluted EPS (ttm)
3.53
Balance Sheet and Cash Flow
Total Cash (mrq)
41.55B
Total Debt/Equity (mrq)
85.70%
Levered Free Cash Flow (ttm)
77.73B
Research Analysis: NVO
View MoreResearch Reports: NVO
View MoreNovo Nordisk Faces Obesity Competition, but Innovation Still Warrants a Wide Moat
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
RatingPrice TargetMorningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover
In this edition, the US-China truce could be the real deal or a mirage; China home prices should stabilize in 2025; Coinbase breach damage should be manageable; and Novo Nordisk, Atlas Copco Class A, and UnitedHealth Group. .
Novo Nordisk: CEO's Surprise Departure Points to Challenging Obesity Market Dynamics
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
RatingPrice TargetBiopharma Industry: Latest Executive Order Threatens Broad Cut to US Drug Prices
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
RatingPrice Target